regulatory approval

A company cannot simply decide its drug is good and start selling it. A government agency must first weigh the evidence and grant permission. Regulatory approval is that authorization: the official decision by a body such as the FDA in the United States or the EMA in Europe that a drug's benefits outweigh its risks for a defined use, allowing it to be marketed to patients.

Approval follows the submission of a comprehensive dossier — a new drug application or marketing authorization application — that gathers all the evidence: the chemistry and manufacturing controls, the preclinical pharmacology and toxicology, and especially the pivotal clinical trial results. Reviewers, sometimes advised by independent expert committees, scrutinize whether the data genuinely support the claimed efficacy and characterize the safety profile. They also approve the precise label: the specific disease, patient population, dose, and warnings under which the drug may be sold.

It is important to understand what approval is and is not. It permits marketing for the approved indication; it is not a guarantee of safety, and it is not the same as a patent, which is a separate legal right. Approval is also not permanent or unconditional — it can carry post-marketing study requirements, can be granted conditionally on a smaller dataset, and can be withdrawn if later evidence shifts the balance of benefit and risk.